??????????????????????

????

□□□□□□□□□ real-world evidence □ RWE
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ real-world study □ RWS
□□□□□□□□□□□□□□□□□□□

□□□

?????????????

□□□

□□□

□□□

□ **8**□□□□

□□□□

□ 1 □
□□□

????????

□□□

□□□

??????????????

□□□

□□□□	□□
□□□ Registry□	□□□□

□□□□	□□
□□□□□ External Control□	□□□□□

□□	□□
□□□□	Data Linkage
□□□□	Data Element
□□□□	Data Curation
□□□□□	Common Data Model, CDM
□□□□	External Control
□□□	Source Data
□□□□□	Health Information System, HIS
□□□□□	Health Service Registries
□□□□□	Product Registry
□□□□□	Real World Data, RWD
□□□□□	Real World Research/Study, RWR/RWS
□□□□□	Real World Evidence, RWE
□□□□	Quality Control, QC
□□□□	Drug Registration
□□□□	Attributable
□□□	Legible
□□□	Contemporaneous
□□□	Original
□□□	Accurate
□□□	Complete
□□□	Consistent
□□□	Enduring
□□□□	Available When Needed

????

[1] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□□□□□ . 2020.1

[2] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□□□□□ . 2021.4

[3] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□□□□□ . 2021.12

[4] AHRQ. Registries for Evaluating Patient Outcomes A User's Guide. 4th Edition. 2020.9

[5] EMA. Guideline on Registry-based Studies. 2021.12

[6] FDA. Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products. 2023.12

[7] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ 2020.8

[8] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□ 2022.1

[9] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□ 2022.6

[10] □□□□□□□□□ . □□ 2023.3

[11] FDA. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products (Draft). 2023.2

[12] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□ . 2023.2

[13] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□ . 2016.7

[14] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□ . 2020.7

[15] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□ . 2016.7

[16] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ . 2023.2

Revision #3
Created 2026-01-15 12:29:37 UTC by Colin Wang
Updated 2026-01-15 12:43:53 UTC by Colin Wang